Sudarshan Pharma to Acquire 76% Stake in Vizag Company

Sudarshan Pharma Industries Ltd has signed a Memorandum of Understanding (MoU) to acquire a 76% stake in a pharmaceutical company located in Vizag, Vishakhapatanam.

What just happened

The company plans to buy 1.2464 crore equity shares, representing 76% of the paid-up capital in the target Vizag-based firm. The consideration will be paid in cash and 40 lakh shares of Sudarshan Pharma offered by its promoters.

Why this matters

This acquisition aims for backward integration, establishing complete end-to-end manufacturing capabilities within Sudarshan Pharma. The target company has a plant with four blocks and a total capacity of 576.10 KL, holding accreditations from US FDA, WHO Geneva, and Anvisa.

The backstory

Sudarshan Pharma Industries has been focused on expanding its market presence. This strategic move into backward integration is expected to bolster its manufacturing operations and product control.

What changes now

Upon completion, the Vizag-based company will become a subsidiary of Sudarshan Pharma Industries. The transaction is expected to be completed by October 10, 2026, pending due diligence and approvals.

Risks to watch

The deal is contingent on successful completion of due diligence and regulatory approvals. Valuation and integration risks associated with the manufacturing plant and its team are key points for monitoring.

Peer comparison

While specific peer acquisitions are not detailed in the filing, the move aligns with industry trends of consolidating supply chains for greater efficiency and cost control.

Context metrics (time-bound)

The target company reported turnovers of Rs 192.47 crore in FY24, Rs 153.55 crore in FY25, and is projected to reach Rs 154.37 crore in FY26.

What to track next

Investors should closely watch the progress of due diligence, finalization of definitive agreements, and the regulatory approval process. The successful integration of the acquired assets will be crucial.